Corporate M&A pace gathers momentum

Intensifying franchise competition, maturing product development pipelines and looming loss of exclusivity spur renewed merger and acquisition (M&A) activity in the ophthalmics sector. Rod McNeil reviews recent deals and related strategic developments. AbbVie to acquire Allergan in $63 billion mega-combination,...

Coming to terms with AI

A machine might be called intelligent if its response to questions could convince a person that it was human, a test proposed by Alan Turing in 1950 [1]. The author considers potential applications of artificial intelligence (AI) using machine learning...

Sharing best practice and landmark evidence in glaucoma care

Evolving technology, best practice and landmark evidence in glaucoma care were reviewed by an international expert faculty in session presentations and debates during the 11th Moorfields International Glaucoma Symposium 2019. The authors were meeting chairs and provide an overview of...

Quality matters in the management of serious eye disorders

The author discusses the first quality standard for serious eye disorders from NICE and takes a look at new care models for enhanced service delivery. Patient backlogs pose risks to patient safety, with research showing that people are losing sight...

The ‘theatre of the mind’: Charles Bonnet Syndrome and Esme’s Umbrella

The founder of Esme’s Umbrella shares her experience with the poorly understood condition Charles Bonnet Syndrome and the creation of the campaign. Many years ago, when I was a young actress, I was in an American play called ‘Butterflies are...

Childhood glaucoma

When a child is given a diagnosis of glaucoma, the impact upon that child and their family is enormous; equivalent to the diagnosis of a cancer [14]. This article outlines the knowledge, techniques and approaches that offer solutions to the...

Eye disease patients have more opportunity than ever to take part in NHS research studies

A new report highlights how 76% of UK hospitals now offer patients the opportunity to take part in studies of eye disease to improve research and innovation. ‘Ophthalmology research in the UK’s National Health Service: the structure and performance of...

Best way to detect glaucoma progression: by reflecting on the past 25 years

Glaucoma – a condition of optic neuropathy leading to progressive visual field loss often associated with raised intraocular pressure. It is fair to say that our definition for this condition has remained unchanged over the last 25 years and the...

Well-presented scholarly research work will reduce chances of journal rebuttal

Submitting to an academic journal? Are you aware of the requirements and constraints of relevant copyright laws? Rod McNeil provides a guide for aspiring authors. Getting published in peer-reviewed academic and medical journals is not easy. But careful attention to...

The International Council of Ophthalmology: what is it and is it useful for UK ophthalmologists?

ICO Director for Examinations and Assessments, Simon Keightley, explains the history and role of the organisation today, as well as outlining recent changes to the ICO examinations. The International Council of Ophthalmology (ICO) is the only international medical specialty organisation...

Globes in space: What would happen to our globes on the globe of Mars?

Many films have been made regarding life on alternative planets. With the Mars One mission approaching in 2023, there are high expectations regarding future interplanetary travel. The authors provide an ophthalmology perspective on what could happen to our eyes if...

Refined glaucoma referral practice offers prospect of improved capacity and expanded role for primary eye care professionals

Glaucoma is the most frequent cause of irreversible blindness worldwide and the second leading cause of blindness in the UK [1,2]. The global prevalence of glaucoma in 2010 was approximately 3.5% for people aged 40-80 years, according to Jonas et...